CancerFax

Shout out to our newest followers! Excited to have you onboard! Louise Karasiak, Toni Marie, Michael Wellendorf, Muhammad Shoaib Hashmi

Today is World Thalassemia Day.

For decades, transfusion-dependent beta-thalassemia has meant a lifetime of monthly transfusions, iron chelation, and the constant management of complications. For many families, especially across India, South Asia, the MENA region, and the CIS, it has meant building life around the rhythm of the transfusion clinic.

That picture is finally changing.
Two gene therapies for transfusion-dependent beta-thalassemia are now approved internationally. For eligible , they offer the possibility of transfusion independence after a single . The that took thirty years to mature is here.

The remaining problem is access.
Current pricing places these therapies out of reach for almost every family in the regions where the disease burden is highest. The infrastructure to deliver them, cell processing, lentiviral vector supply, conditioning protocols, and long-term follow-up exists in only a handful of centers worldwide.

Closing that gap is the work that matters now.

Localization of manufacturing. transfer to high-burden countries. Regulatory pathways that move at the pace patients need. Hospital readiness for cell and gene therapy delivery. Pricing structures that reflect the populations being served.

CancerFax works alongside families navigating advanced hematologic conditions, including transfusion-dependent thalassemia, sickle cell disease, and related disorders. We help patients understand their options, access second opinions from leading hematology centers, evaluate eligibility for advanced therapies and clinical trials, and coordinate cross-border care where required.

If you are a family seeking guidance, a clinician with a complex case, or a partner working on access pathways for hematologic diseases, we would like to hear from you.

Patient services: [email protected] WhatsApp / WeChat: +86 182 1759 2149

A 54-year-old woman from Eastern Europe was told her metastatic breast cancer had no further options.

When her file came to us, three things stood out:

1. She had never had comprehensive genomic profiling
2. Her HER2 status had only been tested by IHC, never by FISH or NGS
3. Her oncologist hadn't considered HER2-low classification, a category that opens up trastuzumab deruxtecan and changes the entire treatment conversation

We weren't doing anything magical. We were doing what a precision oncology workup should have done at diagnosis.

This is the gap that kills people.

Not the absence of treatment.

The absence of someone asking the right questions early enough.

If you're a patient or caregiver reading this , comprehensive genomic profiling at diagnosis is no longer optional in advanced cancer. It's the single most important predictor of whether you'll find the right therapy.

CancerFax is a global cancer access platform.

We help international patients reach advanced treatments, clinical trials, and second opinions across the US, India, China, and beyond.

What we do:
→ Clinical case review by qualified medical staff (PhD Biotech, PharmD)
→ International treatment navigation across 4 continents
→ Access to clinical trials and advanced therapies — CAR-T, oncolytic viruses, gene therapies, precision oncology
→ Cross-border coordination from diagnosis to follow-up

Who we serve:

Patients, families, and referring physicians who need clarity in some of the most difficult decisions of their lives.

Follow this page for clinical insights, treatment landscape updates, and what's actually happening in global cancer care.